Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone and Dapagliflozin for Albuminuric Chronic Kidney Disease
2022-000740-29Phase 2Completed
- Sponsor
- Aarhus University Hospital
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in chronic kidney disease (CKD) comparing Finerenone arm, Dapagliflozin arm and Finerenone + Dapagliflozin arm (3 arms). Primary endpoint: Change in albuminuria after combined treatment. Started Mar 2022; status: completed.
02
Drugs
finerenonedapagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2022-000740-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000740-29.